PART I Overview We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. Galinpepimut-S: Highly Novel and Engineered Immunotherapy Targeting the WT1 Antigen Our le...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-19 | 2025-12-31 | 0001390478-26-000003 | EDGAR | 101K words |
| 2025-03-20 | 2024-12-31 | 0001390478-25-000003 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001390478-24-000004 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0001390478-23-000005 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001390478-22-000006 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001390478-21-000007 | EDGAR | — |
| 2020-03-13 | 2019-12-31 | 0001390478-20-000007 | EDGAR | — |
| 2019-03-22 | 2018-12-31 | 0001390478-19-000017 | EDGAR | — |
| 2018-04-13 | 2017-12-31 | 0001193125-18-117053 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001390478-17-000020 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001390478-25-000020 | EDGAR | 16K words |
| 2025-08-12 | 2025-06-30 | 0001390478-25-000016 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001390478-25-000008 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001390478-24-000021 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001390478-24-000015 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001390478-24-000010 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001390478-23-000024 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001390478-23-000019 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001390478-23-000012 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001390478-22-000028 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001390478-22-000020 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001390478-22-000012 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001390478-26-000004 | EDGAR | 2K words |
| 2026-03-11 | 0001104659-26-026384 | EDGAR | — |
| 2026-01-08 | 0001104659-26-001957 | EDGAR | — |
| 2025-11-12 | 0001390478-25-000021 | EDGAR | — |
| 2025-10-27 | 0001104659-25-102345 | EDGAR | — |
| 2025-10-03 | 0001104659-25-096643 | EDGAR | — |
| 2025-09-11 | 0001104659-25-089272 | EDGAR | — |
| 2025-08-12 | 0001390478-25-000017 | EDGAR | — |
| 2025-06-18 | 0001104659-25-060704 | EDGAR | — |
| 2025-06-06 | 0001104659-25-057308 | EDGAR | — |
432 total filings indexed. 400 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001390478 |
| Ticker | SLS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.sellaslifesciences.com |
| Listed | 2008-03-12 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report